Literature DB >> 14503665

Atrial natriuretic peptide contributes to the antihypertensive action of many drugs.

C L Papadopoulos1, B A Kokkas.   

Abstract

Data derived from a 10 years research program of our team demonstrate that many categories of antihypertensive drugs like beta-adrenergic blockers, alpha1-adrenergic blockers, ACE inhibitors, AT1-receptor antagonists and calcium-entry blockers increase plasma atrial natriuretic peptide (ANP) levels after a medium-term treatment of patients suffering from moderate essential hypertension. ANP always increases despite the drop of the arterial pressure and the fact that the left atrial and ventricular diameters remain unchanged or slightly reduced. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical overload in the left cardiac chambers but the result of a pharmacological action. In conclusion, ANP is a universal factor contributing to the antihypertensive action of many drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503665     DOI: 10.1007/BF03190867

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  19 in total

1.  Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.

Authors:  Panagiotis Kotridis; Basile Kokkas; Michalis Karamouzis; George Sakadamis; Ioannis Kanonidis; George Dadous; Chrisoula Karantona; Olga Gouli; Joshef Karadoumanis; Pavlos C Papadopoulos; Constantine L Papadopoulos
Journal:  Blood Press       Date:  2002       Impact factor: 2.835

2.  Beta-blockers and atrial natriuretic peptide (ANP) in hypertension.

Authors:  C L Papadopoulos; B A Kokkas; G A Anogiannakis
Journal:  Int J Immunopathol Pharmacol       Date:  2000 May-Aug       Impact factor: 3.219

3.  Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension.

Authors:  M Hollenbeck; J Plum; P Heering; B Kutkuhn; B Grabensee
Journal:  J Hypertens       Date:  1991-09       Impact factor: 4.844

4.  Beta-adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides.

Authors:  T Yoshimoto; M Naruse; K Irie; A Tanabe; T Seki; M Tanaka; T Imaki; K Naruse; T Muraki; Y Matsuda; H Demura
Journal:  Eur J Pharmacol       Date:  1998-06-12       Impact factor: 4.432

5.  Increase of plasma atrial natriuretic peptide levels after sublingual administration of nifedipine in essentially hypertensive patients.

Authors:  A Rappelli; P Dessì-Fulgheri; F Bandiera; G Di Noto
Journal:  Int J Cardiol       Date:  1989       Impact factor: 4.164

6.  Regulation of atrial natriuretic factor-(99-126) secretion from neonatal rat primary atrial cultures by activators of protein kinases A and C.

Authors:  P P Shields; C C Glembotski
Journal:  J Biol Chem       Date:  1989-06-05       Impact factor: 5.157

7.  Differential effects of nifedipine on plasma atrial natriuretic peptide in normal subjects and hypertensive patients.

Authors:  S Shigematsu; T Yamada; T Aizawa; N Takasu; Z Shimizu
Journal:  Angiology       Date:  1992-01       Impact factor: 3.619

8.  The role of atrial natriuretic peptide in the diuretic effect of Ca2+ entry blockers.

Authors:  A Shamiss; E Peleg; T Rosenthal; D Ezra
Journal:  Eur J Pharmacol       Date:  1993-03-16       Impact factor: 4.432

9.  Effects of nitrendipine on blood pressure, renin-angiotensin-system and atrial natriuretic peptide in hypertensive type I diabetic patients.

Authors:  H Lehnert; H Schmitz; K Preuss; E Küstner; U Krause; J Beyer
Journal:  Horm Metab Res       Date:  1993-01       Impact factor: 2.936

10.  Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-aldosterone system, and blood pressure in essential hypertension.

Authors:  G Cerasola; S Cottone; M T Mangano; G D'Ignoto; A Pinto; M B Carone
Journal:  Clin Ther       Date:  1988       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.